Quando confrontado com situações de medo os roedores apresentam respostas comportamentais (ex., luta, fuga, imobilidade e vocalização) e neurovegetativas (taquicardia, hipertensão e defecação) que caracterizam a reação de defesa. Em geral essas respostas são acompanhadas de antinocicepção. Estudos demonstram um papel do óxido nítrico (NO) e de receptores NMDA (N-metil-D-aspartato) na mediação de respostas nociceptivas no corno dorsal da medula espinal. Resultados do nosso laboratório demonstraram que a exposição a uma situação ameaçadora, como o labirinto em cruz elevado aberto ou sem paredes (LCEa), provoca antinocicepção de alta magnitude em ratos e camundongos. Assim, o presente estudo teve por objetivo investigar o papel do complexo receptor glutamato/NMDA e NO no corno dorsal da medula espinal na resposta antinociceptiva induzida pela exposição ao LCEa. Camundongos receberam injeção por via intratecal (i.t.) de NMDA (0; 0,4 ou 0,8 nmol/5,0 l) para avaliar seus efeitos intrínsecos sobre a nocicepção. Enquanto a dose de 0,8 nmol de NMDA provocou efeitos nociceptivos, a dose de 0,4 nmol se mostrou desprovida de efeitos. Em seguida, nosso estudo avaliou os efeitos do NMDA (0; 0,1; 0,2 ou 0,4 nmol, i.t.) na nocicepção induzida pela injeção de formalina 2,5% na pata traseira direita do camundongo. Nenhuma dose de NMDA aumentou o tempo de lambidas na pata durante os 10 minutos do teste. Assim, investigamos os efeitos da injeção i.t. de NMDA (0; 0,1; 0,2 ou 0,4 nmol) na antinocicepção induzida pela exposição ao ambiente aversivo (LCEa) ou não aversivo (LCE fechado: quatro braços com paredes; LCEf) em camundongos pré-tratados com formalina a 2,5% na pata traseira direita, durante 10 minutos. O tratamento com NMDA (0,4 nmol) reverteu parcialmente a antinocicepção induzida pela exposição ao LCEa, sem afetar a resposta dos animais expostos ao LCEf. Para avaliar se os efeitos anti-antinociceptivos do NMDA (0,4 nmol) dependem da síntese de NO, camundongos receberam injeção i.t. combinada de L-NAME (N-nitro-L-arginina-metil-éster), um inibidor da NOS, e NMDA. O pré-tratamento com L-NAME (40 nmoles/5,0 l i.t.) bloqueou seletivamente os efeitos anti-antinociceptivos do NMDA. Tomados em conjunto, nossos resultados sugerem que a antinocicepção induzida pela exposição ao LCEa pode ser parcialmente revertida pela ativação de receptores NMDA e indicam que esse efeito depende da síntese de NO no corno dorsal da medula espinal de camundongos. / Rodents exposed to threatening situations (e.g., prey-predator interactions) usually display defensive behaviors (e.g., fight, flight, freezing, vocalization), and neurovegetative (e.g., tachycardia, hypertension, defecation) responses characterized as a fear reaction. Commonly, these responses are accompanied by antinociception. Evidence showing that the glutamate NMDA (N-methyl-d-aspartate) receptor and nitric oxide (NO) complex located within the dorsal horn of the spinal cord in the mediation of the nociceptive response have instigated researchers to investigate the role of the NMDA/NO on some types of fear-induced antinociception. This study investigated the role of the glutamate-NMDA receptor complex and NO in the dorsal horn of the spinal cord of mice in the antinociception induced by a potentially aversive situation, i.e., an exposure to an open elevated plus maze (oEPM: four open arms). Mice were intrathecally (i.t.) injected with N-methyl-D-aspartic acid (NMDA: 0, 0.4 or 0.8 nmol/5.0 l) to assess its intrinsic effects upon nociception. Results showed that NMDA at 0.8 nmol, but not at 0.4 nmol, was able to induce intrinsic nociceptive effect. When injected in animals pre-treated with formalin 2.5% into the right hind paw (nociceptive test), NMDA (0, 0.1, 0.2 or 0.4 nmol, i.t.) did not change time spent licking the formalin injected paw. Then, we investigated the effects of NMDA injection (0, 0.1, 0.2 or 0.4 nmol, i.t.) on nociceptive response induced by formalin test in mice exposed to the oEPM (aversive situation) or enclosed EPM (eEPM: four enclosed arms; control situation) for 10 minutes. NMDA treatment (0.4 nmol) partially reversed the antinociception induced by oEPM exposure without affect nociception in mice exposed to the eEPM. Finally, we investigated whether the anti-antinociceptive effect of NMDA would be dependent on NO synthesis by injecting L-NAME (N-nitro-L-arginine-methyl-ester) i.t., a inhibitor of NOS (nitric oxide synthase), 10 minutes before NMDA injection. L-NAME pretreatment (40 nmol/5.0 l; i.t.) selectivelly blocked anti-antinociceptive effect of NMDA 0.4 nmol. Taken together, our results suggest that antinociception induced by oEPM exposure (i) is, at least in part, reversed by NMDA receptors activation and (ii) this NMDA effect seems to be dependent on NO synthesis within the dorsal horn of the spinal cord in mice.

The mammalian central nervous system maintains a delicate balance between neuronal excitation and inhibition. Conventional synaptic inhibition is mediated through the transient activity of postsynaptic γ-aminobutyric acid (GABA) at type A GABA (GABAA) receptors. A subset of GABAA receptors is also located outside of inhibitory synapses. These extrasynaptic receptors generate a tonic inhibitory conductance in response to low concentrations of extracellular GABA. Tonic inhibition broadly suppresses neuronal activity and regulates many vital processes such as sleep, consciousness and memory formation. This thesis examines the physiological effects of tonic inhibition at the cellular level and in the behaving animal. This thesis also explores whether gabapentin, a commonly used sedative, anxiolytic, and analgesic drug, enhances tonic GABAergic inhibition. I hypothesize that: (1) tonic GABAA receptor activity reduces the intrinsic excitability of neurons; (2) the activity of tonically active GABAA receptors in spinal pain pathways attenuates nociception; and (3) tonic inhibition can be upregulated by gabapentin. The results show that a tonic inhibitory current generated by α5 subunit-containing GABAA (α5GABAA) receptors reduces the excitability of hippocampal pyramidal neurons excitability by increasing the rheobase, but does not change the gain of action potential firing. A similar shunting inhibition is present in spinal cord lamina II neurons that is generated by δ subunit-containing GABAA receptors. The activity of these receptors in spinal nociceptive pathways reduces acute thermal nociception and may constrain central sensitization in a behavioural model of persistent pain. Finally, gabapentin increases a tonic inhibitory current in cultured hippocampal neurons independent from changes in the expression of α5GABAA receptors or in the concentration of GABAA receptor ligands. The results of this thesis demonstrate that tonically active GABAA receptors play an important role in the regulation of neuronal activity and nociception, and that tonic inhibition represents a novel target of therapeutic drugs.

Quando confrontado com situações de medo os roedores apresentam respostas comportamentais (ex., luta, fuga, imobilidade e vocalização) e neurovegetativas (taquicardia, hipertensão e defecação) que caracterizam a reação de defesa. Em geral essas respostas são acompanhadas de antinocicepção. Estudos demonstram um papel do óxido nítrico (NO) e de receptores NMDA (N-metil-D-aspartato) na mediação de respostas nociceptivas no corno dorsal da medula espinal. Resultados do nosso laboratório demonstraram que a exposição a uma situação ameaçadora, como o labirinto em cruz elevado aberto ou sem paredes (LCEa), provoca antinocicepção de alta magnitude em ratos e camundongos. Assim, o presente estudo teve por objetivo investigar o papel do complexo receptor glutamato/NMDA e NO no corno dorsal da medula espinal na resposta antinociceptiva induzida pela exposição ao LCEa. Camundongos receberam injeção por via intratecal (i.t.) de NMDA (0; 0,4 ou 0,8 nmol/5,0 l) para avaliar seus efeitos intrínsecos sobre a nocicepção. Enquanto a dose de 0,8 nmol de NMDA provocou efeitos nociceptivos, a dose de 0,4 nmol se mostrou desprovida de efeitos. Em seguida, nosso estudo avaliou os efeitos do NMDA (0; 0,1; 0,2 ou 0,4 nmol, i.t.) na nocicepção induzida pela injeção de formalina 2,5% na pata traseira direita do camundongo. Nenhuma dose de NMDA aumentou o tempo de lambidas na pata durante os 10 minutos do teste. Assim, investigamos os efeitos da injeção i.t. de NMDA (0; 0,1; 0,2 ou 0,4 nmol) na antinocicepção induzida pela exposição ao ambiente aversivo (LCEa) ou não aversivo (LCE fechado: quatro braços com paredes; LCEf) em camundongos pré-tratados com formalina a 2,5% na pata traseira direita, durante 10 minutos. O tratamento com NMDA (0,4 nmol) reverteu parcialmente a antinocicepção induzida pela exposição ao LCEa, sem afetar a resposta dos animais expostos ao LCEf. Para avaliar se os efeitos anti-antinociceptivos do NMDA (0,4 nmol) dependem da síntese de NO, camundongos receberam injeção i.t. combinada de L-NAME (N-nitro-L-arginina-metil-éster), um inibidor da NOS, e NMDA. O pré-tratamento com L-NAME (40 nmoles/5,0 l i.t.) bloqueou seletivamente os efeitos anti-antinociceptivos do NMDA. Tomados em conjunto, nossos resultados sugerem que a antinocicepção induzida pela exposição ao LCEa pode ser parcialmente revertida pela ativação de receptores NMDA e indicam que esse efeito depende da síntese de NO no corno dorsal da medula espinal de camundongos. / Rodents exposed to threatening situations (e.g., prey-predator interactions) usually display defensive behaviors (e.g., fight, flight, freezing, vocalization), and neurovegetative (e.g., tachycardia, hypertension, defecation) responses characterized as a fear reaction. Commonly, these responses are accompanied by antinociception. Evidence showing that the glutamate NMDA (N-methyl-d-aspartate) receptor and nitric oxide (NO) complex located within the dorsal horn of the spinal cord in the mediation of the nociceptive response have instigated researchers to investigate the role of the NMDA/NO on some types of fear-induced antinociception. This study investigated the role of the glutamate-NMDA receptor complex and NO in the dorsal horn of the spinal cord of mice in the antinociception induced by a potentially aversive situation, i.e., an exposure to an open elevated plus maze (oEPM: four open arms). Mice were intrathecally (i.t.) injected with N-methyl-D-aspartic acid (NMDA: 0, 0.4 or 0.8 nmol/5.0 l) to assess its intrinsic effects upon nociception. Results showed that NMDA at 0.8 nmol, but not at 0.4 nmol, was able to induce intrinsic nociceptive effect. When injected in animals pre-treated with formalin 2.5% into the right hind paw (nociceptive test), NMDA (0, 0.1, 0.2 or 0.4 nmol, i.t.) did not change time spent licking the formalin injected paw. Then, we investigated the effects of NMDA injection (0, 0.1, 0.2 or 0.4 nmol, i.t.) on nociceptive response induced by formalin test in mice exposed to the oEPM (aversive situation) or enclosed EPM (eEPM: four enclosed arms; control situation) for 10 minutes. NMDA treatment (0.4 nmol) partially reversed the antinociception induced by oEPM exposure without affect nociception in mice exposed to the eEPM. Finally, we investigated whether the anti-antinociceptive effect of NMDA would be dependent on NO synthesis by injecting L-NAME (N-nitro-L-arginine-methyl-ester) i.t., a inhibitor of NOS (nitric oxide synthase), 10 minutes before NMDA injection. L-NAME pretreatment (40 nmol/5.0 l; i.t.) selectivelly blocked anti-antinociceptive effect of NMDA 0.4 nmol. Taken together, our results suggest that antinociception induced by oEPM exposure (i) is, at least in part, reversed by NMDA receptors activation and (ii) this NMDA effect seems to be dependent on NO synthesis within the dorsal horn of the spinal cord in mice.

En état de douleur chronique, la sensibilisation centrale s’accompagne d’une modification de l’équilibre excitation/inhibition en faveur d’une excitation accrue de la corne dorsale de la moelle épinière. Cet équilibre implique des molécules d’adhérence telles que les neuroligines postsynaptiques (NLs). Dans une première partie de notre travail de thèse, nous avons étudié la régulation éventuelle de ces protéines dans un modèle de douleur neuropathique (Spinal Nerve Ligation, SNL) chez le rat. Nos données ont montré une surexpression inattendue de la NL2, généralement associée à l’inhibition, alors que l’expression de la NL1, généralement associée à l’excitation, ne change pas. Le blocage de l’expression de NL2 in vivo par application intrathécale de siRNA, a produit des effets anti-nociceptifs réversant de façon significative l’allodynie mécanique observée chez les rats SNL. L’étude ultérieure des partenaires pré- et postsynaptiques de NL2, a démontré une co-variation spécifique avec PSD95, une protéine d’échafaudage des synapses excitatrices. De plus, une approche par co-immunoprécipitation a mis en évidence une augmentation significative des interactions protéiques NL2 /PSD95 chez les rats SNL. Enfin, cette association inhabituelle en condition neuropathique, est apparue liée à la surexpression spécifique de NL2(-), un variant d’épissage de NL2 normalement minoritaire en condition physiologique. La surexpression, l’augmentation d’association avec PSD95, et l’effet pro-nociceptif inattendu de la NL2 « inhibitrice » en condition de douleur neuropathique, indiquent une permutation fonctionnelle de la NL2 de l’inhibition vers l’excitation modifiant le rapport synaptique en faveur d’une excitation globale plus élevée dans la corne dorsale.Dans une deuxième partie du travail, nous avons exploré le rôle des molécules d’adhérence NLs dans la sensibilisation spinale associée à un autre type de douleur chronique, à savoir la douleur cancéreuse, sur un modèle de cancer de l’os chez le rat. L’étude de l’expression des NLs et de leurs partenaires, a montré une augmentation d’expression spécifique de la NL1 et de S-SCAM, une autre protéine d’échafaudage des synapses excitatrices. D’autre part, d’après la littérature, ce modèle se caractérise par une importante activation gliale dans les cornes dorsales de la moelle épinière, se traduisant notamment par une astrogliose massive. Cependant, nous avons montré que dans le modèle utilisé, il n’y avait aucune variation ni de marqueurs classiques de l’activation astrocytaire (GFAP, S100β), ni des marqueurs microgliaux (OX-42 et Iba1). Au contraire, tous ces paramètres étaient effectivement augmentés dans la corne dorsale ipsilatérale d’animaux neuropathiques. Ces résultats suggèrent que, contrairement à ce qui a été décrit précédemment, la douleur cancéreuse d’origine osseuse n’est pas nécessairement corrélée à une surexpression spinale des marqueurs de la glie réactive, tandis que la douleur neuropathique l’est.En conclusion, nos résultats obtenus dans le modèle de douleur cancéreuse montrent un phénotype concernant des molécules impliquées dans la formation, la spécification et la modulation des synapses, bien différent de celui que nous avons mis en évidence dans le modèle de douleur neuropathique. Nous montrons notamment dans les deux modèles, une implication bien distincte des molécules d’adhérence NLs et de la glie confortant les données de la littérature indiquant que ces deux grandes catégories de douleur chronique ont chacune une signature propre. De plus, nos résultats ouvrent la perspective d’identifier de nouveaux diagnostics et/ou de nouvelles possibilités thérapeutiques, en ciblant spécifiquement les NLs. / In chronic pain states, central sensitization is associated with a modification in the excitation/inhibition balance toward increased excitation in the spinal dorsal horn. This balance involves adhesion molecules such as the postsynaptic Neuroligins (NLs). In a first part of our thesis work, we investigated the putative regulation of these proteins in the Spinal Nerve Ligation (SNL) model of neuropathy in the rat. Our data showed an unexpected upregulation of NL2, usually associated to inhibition, whereas expression of NL1, usually associated to excitation, did not change. The in vivo expression blockade of NL2 by intrathecal injection of siRNAs, produced specific antinociceptive effects, significantly reversing the SNL-induced mechanical allodynia. Subsequent study of pre- and postsynaptic NL2 partners, demonstrated a specific co-variation with PSD95, a scaffolding protein of excitatory synapses. Moreover, a co-immunoprecipitation approach showed a significant increase of NL2/PSD95 protein interactions in SNL rats. Finally, this unusual association in neuropathic conditions, appeared to be linked to specific over-expression of NL2(-), a NL2 splice variant usually a minority in physiological conditions. Over-expression, increased association with PSD95, and unexpected pronociceptive effect of the “inhibitory” NL2 in neuropathic pain condition, suggest a functional shift of NL2 from inhibition to excitation changing the synaptic ratio toward higher overall excitation in the dorsal horn.In a second part of our work, we investigated the role of the NLs adhesion molecules in spinal sensitization associated with another type of chronic pain, namely cancer pain, using a rat model of bone cancer. The study of the expression of NLs and partners, showed a specific increase in the expression of NL1 and S-SCAM, another postsynaptic scaffolding protein at excitatory synapses. Moreover, according to the literature, this model is characterized by a strong glial activation in the spinal dorsal horn, identified especially by a massive astrogliosis. However, we showed that in the bone cancer model used, there was no variation, neither in the classical markers of astrocyte activation (GFAP, S100β), nor in microglial markers (OX-42 et Iba1). On the contrary, all these parameters did actually increase in the ipsilateral dorsal horn of SNL neuropathic rats. These results suggest that, at odd with what was previously described, bone cancer pain is not necessarily correlated with a spinal overexpression of markers of reactive glia, whereas neuropathic pain is.In conclusion, our results obtained with the cancer pain model, show that the molecules involved in the formation, specification and modulation of synapses, yield a phenotypes clearly different to the one evidenced in the model of neuropathic pain. More particularly, we show in the two models, a well distinct involvement of the NL adhesion molecules and of glia, reinforcing reports from the literature, which indicate that the two important categories of chronic pain, cancer and neuropathic, each have a peculiar signature. Moreover, our results raise the possibility that new diagnosis and/or new therapeutic possibilities may emerge from targeting NL expression

No description available.

Release of endomorphin (ENDO)-2 like substances from the dorsal horn of the isolated rat spinal cord was measured by the immobilized-antibody microprobe technique. Spinal cords were removed from anesthetized 4-6 week old rats and superfused with oxygenated Krebs solution at room temperature. Glass microprobes coated with ENDO-2 antibodies were inserted into the dorsal horn of the lumbar spinal cord 1.5 mm lateral to the midline to a depth 2.5 mm below the dorsal surface of the cord. Each probe remained in situ for 10 min periods before, during and after electrical stimulation applied to the dorsal root entry zone of the same spinal segment. There was no detectable basal release of immunoreactive endomorphin-2 like substance (irENDO) from the dorsal horns during the pre-stimulation, nor following the stimulation period. A significant release of irENDO was measured during the electrical stimulation. These results provide the first evidence of a irEndo release that is correlated spatially with the dorsal horn laminae I and II where ENDO-2-immunoreactive fibers are concentrated in the dorsal horn in response to electrical activation of primary afferent fibers.

Metastin, the product of metastasis suppressor gene KiSS-1, is proposed to be the natural ligand for the G-protein-coupled receptor GPR54, known also as AXOR12. This immunohistochemical study, using a rabbit polyclonal antiserum against the human metastin fragment (45-54)-NH2, showed that in rats metastin-like immunoreactivity (MTS-LI) was present in neurons of the nucleus of the solitary tract and caudoventrolateral reticular nucleus, and in cell processes of the spinal trigeminal tract and lateral reticular nucleus. MTS-LI was confined mainly to neurons and fibers at or caudal to the area postrema. In the spinal cord, MTS-LI cell processes formed a dense plexus in superficial layers I and II of the dorsal horn. The pattern of distribution of MTS-LI in the medulla and spinal cord suggests that this novel peptide may participate in autonomic and sensory neural signaling.

Metastin, the gene product of metastasis suppressor gene KiSS-1, is the endogenous ligand for the G-protein-coupled receptor GPR54 (or AXOR12, or OT7T175). The expression of KiSS-1 gene and peptide and the distribution of metastin were studied in the rat central nervous system by reverse transcriptase-polymerase chain reaction, Western blotting, and immunohistochemical methods. KiSS-1 gene and peptide expression was higher in the hypothalamus than in the brainstem and spinal cord. In the brain, metastin-like immunoreactivity (irMT) was found mainly in three groups of cells: dorsomedial hypothalamic nucleus, nucleus of the solitary tract, and caudal ventrolateral medulla. Immunoreactive fibers of varying density were noted in bed nucleus of stria terminalis, septal nuclei, nucleus accumbens, caudate putamen, diagonal band, amygdala, hypothalamus, zona incerta, thalamus, periaqueductal gray, raphe nuclei, lateral parabrachial nucleus, locus coeruleus, spinal trigeminal tract, rostral ventrolateral medulla, and medullary reticular nucleus. Preabsorption of the antiserum with metastin peptide fragment (45-54)-NH2 (1 μg/ml) resulted in no staining in any of the sections. The biological activity of metastin was assessed by monitoring intracellular calcium [Ca2+]i in cultured hippocampal neurons, which are known to express GPR54. Metastin increased [Ca 2+]i in a population of cultured hippocampal neurons. The results show that metastin is biologically active in rat central neurons, and its anatomical distribution suggests a possible role in nociception and autonomic and neuroendocrine functions.

1. Although the ORL1 receptor is clearly located within the spinal cord, the functional signalling mechanism of the ORL1 receptor in the spinal cord has not been clearly documented. The present study was then to investigate the guanine nucleotide binding protein (G-protein) activation mediated through by the ORL1 receptor in the mouse spinal cord, measuring the modulation of guanosine-5'-o-(3-[35S]-thio) triphosphate ([35S]-GTPγS) binding by the putative endogenous ligand nociceptin, also referred as orphanin FQ. We also studied the anatomical distribution of nociceptin-like immunoreactivity and nociceptin-stimulated [35S]-GTPγS autoradiography in the spinal cord. 2. Immunohistochemical staining of mouse spinal cord sections revealed a dense plexus of nociceptin-like immunoreactive fibres in the superficial layers of the dorsal horn throughout the entire length of the spinal cord. In addition, networks of fibres were seen projecting from the lateral border of the dorsal horn to the lateral grey matter and around the central canal. 3. In vitro [35S]-GTPγS autoradiography showed high levels of nociceptin-stimulated [35S]-GTPγS binding in the superficial layers of the mouse dorsal horn and around the central canal, corresponding to the areas where nociceptin-like immunoreactive fibres were concentrated. 4. In [35S]-GTPγS membrane assay, nociceptin increased [35S]-GTPγS binding of mouse spinal cord membranes in a concentration-dependent and saturable manner, affording maximal stimulation of 64.1 ± 2.4%. This effect was markedly inhibited by the specific ORL1 receptor antagonist [Phe1ψ (CH2-NH) Gly2] nociceptin (1-13) NH2. None of the μ-, δ-, and κ-opioid and other G-protein-coupled receptor antagonists had a significant effect on basal or nociceptin-stimulated [35S]-GTPγS binding. 5. These findings suggest that nociceptin-containing fibres terminate in the superficial layers of the dorsal horn and the central canal and that nociceptin released in these areas may selectively stimulate the ORL1 receptor to activate G-protein. Furthermore, the unique pattern of G-protein activation in the present study provide additional evidence that nociceptin is distinct from the μ-, δ- or κ-opioid system.

No description available.